Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Biopharma survey: Shortage of bioprocessing talent key threat to sector

Industry is struggling to find and develop skilled bioprocessing workers according to respondents to NIBRT’s biopharma trends survey.

Boehringer Ingelheim's Humira biosimilar accepted for review in US and Europe

The EMA and US FDA have agreed to review a candidate Humira (adalimumab) biosimilar developed by Boehringer Ingelheim.

Cell preservation prosperity: BioLife and Cryoport up on personalised meds

With increased interest in cell and gene therapies, BioLife Solutons has reported a 28% year-on-year growth in sales of biopreservation media, while Cryoport has struck another logistics deal.

AbbVie’s Humira IP strategy having ‘chilling effect on competition,’ UK judge

A UK judge says a vexatious litigation strategy is staving off Humira biosimilars, but AbbVie is “playing by the rules and incurring the costs of doing so,” according to an IP lawyer.

Pfenex, Pfizer and Sandoz hail US FDA interchangeability guidelines

A clear interchangeability pathway is essential for the US biosimilar market say developers as they begin reviewing the much-welcomed draft FDA guidance.


Servier universal CAR-T therapy outsourced to Belgian CDMO

Servier has recruited CDMO MaSTherCell SA to manufacture its universal CAR-T candidate UCART19, licensed from the biotech Cellectis as an off-the-shelf cell therapy for leukemia.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...